Safflower (Carthamus tinctorius L.) oil could improve abdominal obesity, blood pressure, and insulin resistance in patients with metabolic syndrome: A randomized, double-blind, placebo-controlled clinical trial.
Adiponectin
/ blood
Adult
Anticholesteremic Agents
/ administration & dosage
Antioxidants
/ administration & dosage
Blood Glucose
/ analysis
Blood Pressure Determination
/ methods
Body Mass Index
Carthamus tinctorius
Double-Blind Method
Drug Monitoring
/ methods
Female
Humans
Insulin Resistance
Male
Medicine, Persian
/ methods
Metabolic Syndrome
/ drug therapy
Obesity, Abdominal
/ diagnosis
Phytotherapy
/ methods
Safflower Oil
/ administration & dosage
Treatment Outcome
Carthamus tinctorius
Diabetes mellitus
Insulin resistance
Metabolic syndrome
Safflower oil
Traditional Persian medicine
Journal
Journal of ethnopharmacology
ISSN: 1872-7573
Titre abrégé: J Ethnopharmacol
Pays: Ireland
ID NLM: 7903310
Informations de publication
Date de publication:
10 Jan 2022
10 Jan 2022
Historique:
received:
14
12
2020
revised:
19
05
2021
accepted:
29
08
2021
pubmed:
7
9
2021
medline:
29
1
2022
entrez:
6
9
2021
Statut:
ppublish
Résumé
Carthamus tinctorius L. (Safflower) has been widely recommended to treat metabolic disorders in traditional herbal medicine in Persia, China, Korea, Japan, and other East-Asian countries. The anti-hypercholesterolemic and antioxidant effects of this plant have been well documented, but its protective effects against Metabolic Syndrome (MetS) have not been fully illustrated. The present study aimed to evaluate the effects of safflower oil on MetS risk factors. In this randomized, double-blind, placebo-controlled clinical trial, 67 patients with MetS were administered either divided 8 g safflower oil or placebo daily for 12 weeks. All patients were advised to follow their previous diets and physical activities. Safflower oil resulted in a significant reduction in waist circumference (-2.42 ± 3.24 vs. 0.97 ± 2.53, p<0.001), systolic blood pressure (-8.80 ± 9.77 vs. -2.26 ± 8.56, p = 0.021), diastolic blood pressure (-3.53 ± 7.52 vs. -0.70 ± 6.21, p = 0.041), fasting blood sugar (-5.03 ± 10.62 vs. 2.94 ± 7.57, p = 0.003), and insulin resistance (-0.59 ± 1.43 vs. 0.50 ± 1, p = 0.012), but an increase in adiponectin level (0.38 ± 0.99 vs. -0.09 ± 0.81, p = 0.042) in the treatment group in comparison to the placebo group. The results revealed a direct relationship between leptin level and Body Mass Index (BMI) in both groups (p<0.001). In addition, increase in BMI resulted in a non-significant decrease in adiponectin level in both groups. Moreover, no significant difference was observed between the two groups regarding lipid profiles, leptin serum level, serum creatinine concentration, and other outcomes. Safflower oil without lifestyle modification improved abdominal obesity, blood pressure, and insulin resistance in patients with MetS.
Identifiants
pubmed: 34487844
pii: S0378-8741(21)00819-9
doi: 10.1016/j.jep.2021.114590
pii:
doi:
Substances chimiques
Adiponectin
0
Anticholesteremic Agents
0
Antioxidants
0
Blood Glucose
0
Safflower Oil
8001-23-8
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
114590Informations de copyright
Copyright © 2021 Elsevier B.V. All rights reserved.